<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024462</url>
  </required_header>
  <id_info>
    <org_study_id>YO41137</org_study_id>
    <nct_id>NCT04024462</nct_id>
  </id_info>
  <brief_title>A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer</brief_title>
  <official_title>A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Patients With HER2-Positive Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics, efficacy, and safety of the pertuzumab and&#xD;
      trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) as compared&#xD;
      with those of the pertuzumab intravenous (IV) and trastuzumab IV formulations in Chinese&#xD;
      participants with human epidermal growth factor receptor 2 (HER2)-positive early breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)</measure>
    <time_frame>Pre-dose at Cycle 8 (one cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ctrough of Trastuzumab During Cycle 7 (Pre-Dose Cycle 8)</measure>
    <time_frame>Pre-dose at Cycle 8 (one cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment</measure>
    <time_frame>Following completion of surgery (up to 33 weeks)</time_frame>
    <description>tpCR is defined as eradication of invasive disease in the breast and axilla (i.e., ypT0/isypN0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Invasive Disease-Free Survival (iDFS; Excluding Second Primary Non-Breast Cancer [SPNBC]) Criteria</measure>
    <time_frame>From date of surgery to iDFS (excluding SPNBC) event (up to 5 years)</time_frame>
    <description>iDFS (excluding SPNBC) is defined as the time from the first date of no disease (i.e., the date of primary surgery) to the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer reccurrence; distant recurrence; contralateral invasive breast cancer; or death attributable to any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to iDFS (Including SPNBC) Criteria</measure>
    <time_frame>From date of surgery to iDFS (including SPNBC) event (up to 5 years)</time_frame>
    <description>iDFS including SPNBC is defined in the same way as iDFS but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Event-Free Survival (EFS; Excluding SPNBC) Criteria</measure>
    <time_frame>From baseline to EFS (excluding SPNBC) event (up to 5.5 years)</time_frame>
    <description>EFS (excluding SPNBC) is defined as the time from enrollment to the first occurrence of one of the following events: breast cancer progression; breast cancer recurrence; or death from any cause. Ipsilateral or contralateral in situ disease and SPNBC (including in situ carcinomas and non-melanoma skin cancers) will not be counted as progressive disease or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to EFS (Including SPNBC) Criteria</measure>
    <time_frame>From baseline to EFS (including SPNBC) event (up to 5.5 years)</time_frame>
    <description>EFS including SPNBC is defined in the same way as EFS, but including SPNBC as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Distant Recurrence-Free Interval (DRFI) Criteria</measure>
    <time_frame>From baseline to DFRI event (up to 5.5 years)</time_frame>
    <description>DRFI is defined as the time between randomization and the date of distant breast cancer recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival</measure>
    <time_frame>From baseline to death from any cause (up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with At Least One Adverse Event by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 (NCI CTCAE v4)</measure>
    <time_frame>From baseline until study completion (up to 5.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Symptomatic Ejection Fraction Decrease (Heart Failure) of NYHA Class III or IV and a Drop in Left Ventricular Ejection Fraction (LVEF) of at Least 10-Percentage Points from Baseline and to Below 50%</measure>
    <time_frame>From baseline until study completion (up to 5.5 years)</time_frame>
    <description>New York Heart Association (NYHA) Class III is defined as: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. NYHA Class IV is defined as: Inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died from a Definite or Probable Cardiac Death</measure>
    <time_frame>From baseline until study completion (up to 5.5 years)</time_frame>
    <description>Definite cardiac death is defined as death due to heart failure, myocardial infarction, or documented primary arrhythmia. Probable cardiac death is defined as sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Asymptomatic or Mildly Symptomatic Left Ventricular Systolic Dysfunction (LVSD) of NYHA Class II</measure>
    <time_frame>From baseline until study completion (up to 5.5 years)</time_frame>
    <description>An LVSD (&quot;Ejection fraction decreased&quot;) of NYHA Class II is defined as an LVEF decrease of ≥10-percentage points below the baseline measurement to an absolute LVEF value of &lt;50%, confirmed by a second assessment within approximately 3 weeks confirming a decrease of ≥10-percentage points below the baseline measurement and to an absolute LVEF value of &lt;50%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>HER2-positive Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) of will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the PH FDC SC for a total of 18 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab IV</intervention_name>
    <description>Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <other_name>Perjeta</other_name>
    <other_name>RO4368451</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab IV</intervention_name>
    <description>Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <other_name>Herceptin</other_name>
    <other_name>RO0452317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab and Trastuzumab FDC SC</intervention_name>
    <description>The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.</description>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
    <other_name>Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</other_name>
    <other_name>PHESGO™</other_name>
    <other_name>PH FDC SC</other_name>
    <other_name>RG6264</other_name>
    <other_name>RO7198574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 milligrams per meter squared of body surface area (mg/m^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-Operative Radiotherapy</intervention_name>
    <description>If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Therapy</intervention_name>
    <description>For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.</description>
    <arm_group_label>Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status greater or equal to (≤)1&#xD;
&#xD;
          -  Stage II-IIIC (T2-T4 plus any N, or any T plus N1-3, M0), locally advanced,&#xD;
             inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast&#xD;
             cancer&#xD;
&#xD;
          -  Primary tumor greater than (&gt;)2 centimeters (cm) in diameter, or node-positive disease&#xD;
             (clinically or on imaging, and node positivity confirmed with cytology and/or&#xD;
             histopathology)&#xD;
&#xD;
          -  Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer confirmed by a&#xD;
             central laboratory prior to study enrollment. HER2-positive status will be determined&#xD;
             based on pretreatment breast biopsy material and defined as 3+ by immunohistochemistry&#xD;
             (IHC) and/or positive by HER2 amplification by in situ hybridization (ISH) with a&#xD;
             ratio of ≥2 for the number of HER2 gene copies to the number of signals for chromosome&#xD;
             17 copies&#xD;
&#xD;
          -  Hormone receptor status of the primary tumor, centrally confirmed&#xD;
&#xD;
          -  Patient agreement to undergo mastectomy or breast conserving surgery after neoadjuvant&#xD;
             therapy&#xD;
&#xD;
          -  Availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue for central&#xD;
             confirmation of HER2, hormone receptor status, and PIK3CA mutational analyses&#xD;
&#xD;
          -  Baseline left ventricular ejection fraction (LVEF) ≥55% measured by echocardiogram&#xD;
             (ECHO) or multiple-gated acquisition scan (MUGA)&#xD;
&#xD;
          -  For women of childbearing potential (WOCBP) who are sexually active: agreement to&#xD;
             remain abstinent (refrain from heterosexual intercourse) or use one highly effective&#xD;
             non-hormonal contraceptive method with a failure rate of less than (&lt;)1% per year, or&#xD;
             two effective non-hormonal contraceptive methods during the treatment period and for 7&#xD;
             months after the last dose of HER2-targeted therapy, and agreement to refrain from&#xD;
             donating eggs during this same period&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             a condom in combination with a spermicidal foam, gel, film, cream, or suppository, and&#xD;
             agreement to refrain from donating sperm, as specified in the protocol&#xD;
&#xD;
          -  A negative serum pregnancy test must be available prior to randomization for WOCBP&#xD;
             (premenopausal women and women &lt;12 months after the onset of menopause), unless they&#xD;
             have undergone surgical sterilization (removal of ovaries and/or uterus)&#xD;
&#xD;
          -  No major surgical procedure unrelated to breast cancer within 28 days prior to&#xD;
             randomization or anticipation of the need for major surgery during the course of study&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV (metastatic) breast cancer&#xD;
&#xD;
          -  History of invasive breast cancer&#xD;
&#xD;
          -  History of concurrent or previously treated non-breast malignancies except for&#xD;
             appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas,&#xD;
             including cervix, colon, and skin&#xD;
&#xD;
          -  Have received any previous systemic therapy (including chemotherapy, immunotherapy,&#xD;
             HER2-targeted agents, endocrine therapy [selective estrogen receptor modulators,&#xD;
             aromatase inhibitors], and antitumor vaccines) for treatment or prevention of breast&#xD;
             cancer, or radiation therapy for treatment of cancer&#xD;
&#xD;
          -  Have a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ&#xD;
             (LCIS) if they have received any systemic therapy for its treatment or radiation&#xD;
             therapy to the ipsilateral breast&#xD;
&#xD;
          -  High-risk for breast cancer and have received chemopreventative drugs in the past&#xD;
&#xD;
          -  Multicentric (multiple tumors involving more than one quadrant) breast cancer, unless&#xD;
             all tumors are HER2-positive&#xD;
&#xD;
          -  Bilateral breast cancer&#xD;
&#xD;
          -  Have undergone an excisional biopsy of primary tumor and/or axillary lymph nodes&#xD;
&#xD;
          -  Axillary lymph node dissection (ALND) prior to initiation of neoadjuvant therapy&#xD;
&#xD;
          -  Sentinel lymph node biopsy (SLNB) prior to neoadjuvant therapy&#xD;
&#xD;
          -  Treatment with any investigational drug within 28 days prior to randomization&#xD;
&#xD;
          -  Serious cardiac illness or medical conditions&#xD;
&#xD;
          -  Inadequate bone marrow function&#xD;
&#xD;
          -  Impaired liver function&#xD;
&#xD;
          -  Inadequate renal function with serum creatinine &gt;1.5X upper limit of normal (ULN)&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease that may interfere with planned&#xD;
             treatment (e.g., clinically significant cardiovascular, pulmonary, or metabolic&#xD;
             disease; wound-healing disorders)&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             7 months after the last dose of HER2-targeted therapy&#xD;
&#xD;
          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             investigator's judgment, precludes the patient's safe participation in and completion&#xD;
             of the study&#xD;
&#xD;
          -  Known active liver disease, for example, active viral hepatitis infection (i.e.,&#xD;
             hepatitis B or hepatitis C), autoimmune hepatic disorders, or sclerosing cholangitis&#xD;
&#xD;
          -  Concurrent, serious, uncontrolled infections, or known infection with HIV&#xD;
&#xD;
          -  Known hypersensitivity to study drugs, excipients, and/or murine proteins&#xD;
&#xD;
          -  Current chronic daily treatment with corticosteroids (dose &gt;10 milligrams [mg]&#xD;
             methylprednisolone or equivalent excluding inhaled steroids)&#xD;
&#xD;
          -  History of other malignancy within 5 years prior to screening, except for&#xD;
             appropriately treated carcinoma in situ of the cervix, colon, skin, and/or&#xD;
             non-melanoma skin carcinoma&#xD;
&#xD;
          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such&#xD;
             as structural heart disease (e.g., severe LVSD, left ventricular hypertrophy),&#xD;
             coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic&#xD;
             testing), clinically significant electrolyte abnormalities (e.g., hypokalemia,&#xD;
             hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long&#xD;
             QT syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun City</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <zip>132013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 900th Hospital of PLA joint service support force</name>
      <address>
        <city>Fuzhou</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital; Breast Surgery</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Medical College Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai City</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai City</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan City</city>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xian Jiao Tong University</name>
      <address>
        <city>Xi'an City</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

